Page last updated: 2024-10-27

fluorouracil and Lymphoproliferative Disorders

fluorouracil has been researched along with Lymphoproliferative Disorders in 1 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hao, SX1
Ren, R1

Other Studies

1 other study available for fluorouracil and Lymphoproliferative Disorders

ArticleYear
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Molecular and cellular biology, 2000, Volume: 20, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; B-Lymphocytes; Base Sequence; Bone Marrow Transplantation;

2000